Arcellx (ACLX) Liabilities and Shareholders Equity (2021 - 2025)

Arcellx's (ACLX) quarterly Liabilities and Shareholders Equity came in at $604.0 million in Q4 2025, down 15.09% year-on-year from $711.3 million in Q4 2024, and down 7.92% quarter-over-quarter from $655.9 million in Q3 2025.

Arcellx (ACLX) Liabilities and Shareholders Equity (2021 - 2025) Analysis & Trends

Arcellx's Liabilities and Shareholders Equity history runs 5 years deep, the most recent figure standing at $604.0 million for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 15.09% year-over-year to $604.0 million in Q4 2025; TTM through Dec 2025 was $2.5 billion, a 15.49% decrease from a year earlier, with the FY2025 full-year figure at $604.0 million, down 15.09% from the prior year.
  • Liabilities and Shareholders Equity declined to $604.0 million in Q4 2025 per ACLX's latest filing, from $655.9 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $825.1 million in Q4 2023 and bottomed at $128.8 million in Q4 2021.
  • The 5-year median for Liabilities and Shareholders Equity is $622.9 million (2023), against an average of $565.0 million.
  • Across the five-year window, Liabilities and Shareholders Equity jumped 162.93% in 2023 and declined 16.88% in 2025, its largest moves.
  • Year by year, Liabilities and Shareholders Equity stood at $128.8 million in 2021, then soared by 143.68% to $313.8 million in 2022, then soared by 162.93% to $825.1 million in 2023, then fell by 13.79% to $711.3 million in 2024, then slipped by 15.09% to $604.0 million in 2025.
  • Per Business Quant, the three latest ACLX Liabilities and Shareholders Equity figures stand at $604.0 million (Q4 2025), $655.9 million (Q3 2025), and $619.1 million (Q2 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 311.58 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 78.88 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 8.55 Bn
4 NuCana 279.75 Bn 279.75 Bn - 39.68 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 26.48 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 40.87 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - 811.27 Mn
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 10.03 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 2.25 Bn
10 Arcellx 6.48 Bn 6.48 Bn - 603.99 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 603.99 Mn
Sep 30, 2025 655.92 Mn
Jun 30, 2025 619.09 Mn
Mar 31, 2025 648.08 Mn
Dec 31, 2024 711.33 Mn
Sep 30, 2024 764.91 Mn
Jun 30, 2024 734.31 Mn
Mar 31, 2024 779.70 Mn
Dec 31, 2023 825.13 Mn
Sep 30, 2023 614.22 Mn
Jun 30, 2023 623.53 Mn
Mar 31, 2023 622.94 Mn
Dec 31, 2022 313.82 Mn
Sep 30, 2022 337.33 Mn
Jun 30, 2022 374.66 Mn
Mar 31, 2022 246.98 Mn
Dec 31, 2021 128.78 Mn